Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation

Quiver QuantitativeNov 20 08:12 ET

Express News | Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025

ReutersNov 20 08:01 ET

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

GlobeNewswireNov 20 08:01 ET

Express News | Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of Cdx-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

ReutersNov 20 08:01 ET

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

BenzingaNov 20 07:00 ET

Founder of Celldex Therapeutics Anthony Marucci Buys 40% More Shares

Simply Wall StNov 15 06:17 ET